These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 35772010)

  • 1. Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C.
    Andraka-Christou B; Saloner B; Gordon AJ; Totaram R; Randall-Kosich O; Golan M; Stein BD
    Am J Drug Alcohol Abuse; 2022 Jul; 48(4):492-503. PubMed ID: 35772010
    [No Abstract]   [Full Text] [Related]  

  • 2. Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorder.
    Andraka-Christou B; Clark MH; Atkins DN; Del Pozo B
    Subst Abus; 2022; 43(1):425-432. PubMed ID: 34236297
    [No Abstract]   [Full Text] [Related]  

  • 3. Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019.
    Andraka-Christou B; Golan O; Totaram R; Ohama M; Saloner B; Gordon AJ; Stein BD
    Ann Med; 2023 Dec; 55(1):514-520. PubMed ID: 36724766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
    Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
    J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
    Huhn AS; Hobelmann JG; Strickland JC; Oyler GA; Bergeria CL; Umbricht A; Dunn KE
    JAMA Netw Open; 2020 Feb; 3(2):e1920843. PubMed ID: 32031650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Payment-related barriers to medications for opioid use disorder: A critical review of the literature and real-world application.
    Bowser D; Bohler R; Davis MT; Hodgkin D; Horgan C
    J Subst Use Addict Treat; 2024 Oct; 165():209441. PubMed ID: 38906417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
    Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
    Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
    Andraka-Christou B; Atkins D
    Am J Drug Alcohol Abuse; 2020 Nov; 46(6):749-760. PubMed ID: 32969757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails.
    Flanagan Balawajder E; Ducharme L; Taylor BG; Lamuda PA; Kolak M; Friedmann PD; Pollack HA; Schneider JA
    JAMA Netw Open; 2024 Sep; 7(9):e2434704. PubMed ID: 39316401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 12. Estimating the impact on initiating medications for opioid use disorder of state policies expanding Medicaid and prohibiting substance use during pregnancy.
    Choi S; Stein MD; Raifman J; Rosenbloom D; Clark JA
    Drug Alcohol Depend; 2021 Dec; 229(Pt A):109162. PubMed ID: 34768053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
    Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
    Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
    Pilarinos A; Bromberg DJ; Karamouzian M
    JAMA Pediatr; 2022 Mar; 176(3):304-311. PubMed ID: 34870707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.
    Taylor EN; Timko C; Binswanger IA; Harris AHS; Stimmel M; Smelson D; Finlay AK
    Subst Abus; 2022; 43(1):556-563. PubMed ID: 34586978
    [No Abstract]   [Full Text] [Related]  

  • 16. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
    Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
    Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
    Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
    J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attitudes toward and training in medications for opioid use disorders: a descriptive analysis among employees in the youth legal system and community mental health centers.
    O'Reilly LM; Schwartz K; Brown SA; Dir A; Gillenwater L; Adams Z; Zapolski T; Hulvershorn LA; Aalsma M
    Subst Abuse Treat Prev Policy; 2024 Jun; 19(1):32. PubMed ID: 38907286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatial and Nonspatial Factors Associated with Access to Medication for Opioid Use Disorder among Pregnant Women in Massachusetts.
    Joshi C; Ho Chui KK; Skeer MR; Stopka TJ
    Subst Use Misuse; 2022; 57(13):1904-1917. PubMed ID: 36219099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review.
    Madden EF; Prevedel S; Light T; Sulzer SH
    Subst Use Misuse; 2021; 56(14):2181-2201. PubMed ID: 34538213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.